Document Detail

VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.
MedLine Citation:
PMID:  20676744     Owner:  NLM     Status:  In-Data-Review    
Patients treated with anti-VEGF agents are at increased risk for arterial thrombo-embolic events (ATEs). However, the pathophysiology of such acute vascular complications remains unclear. We report on a case of bowel infarction in a renal cancer patient treated with the anti-VEGF agent sunitinib. An abdominal CT-scan evidenced the rupture of an atherosclerotic plaque located at the emergence of the superior mesenteric artery. In view of this report, we suggest that evaluation of the risk of ATE in patients receiving anti-VEGF agents should include not only age and past history of ATE as suggested by previous studies, but also assessment of atherosclerotic lesions on CT-scan.
Stanislas Ropert; Olivier Vignaux; Olivier Mir; François Goldwasser
Related Documents :
3632384 - The importance of carotid artery plaque disruption and hemorrhage.
9409234 - Compensatory enlargement in coronary and femoral arteries is related to neither the ext...
679694 - Angiometric assessment of coronary atherosclerosis in ischaemic heart disease in elderl...
16463684 - Assessment of coronary flow velocity reserve by noninvasive transthoracic doppler echoc...
19761504 - Atp revealed extra pulmonary vein source of atrial fibrillation after circumferential p...
867324 - Quantitative structural study of pulmonary circulation in the newborn with pulmonary at...
Publication Detail:
Type:  Journal Article     Date:  2010-07-30
Journal Detail:
Title:  Investigational new drugs     Volume:  29     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-09-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1497-9     Citation Subset:  IM    
Centre for Research on Angiogenesis Inhibitors (CERIA), Department of Medical Oncology, AP-HP, Cochin Teaching Hospital, Université Paris Descartes, 27, rue du faubourg saint Jacques, F75014, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal m...
Next Document:  YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pat...